Barbro Linderholm - Concepedia

Author

Barbro Linderholm

Also Known As

B K Linderholm, B Linderholm, B. K. Linderholm, B. Linderholm, B.K. Linderholm, Barbro K Linderholm, Barbro K. Linderholm, Barbro Kristina Linderholm, Barbro Linderholm, Barbro Lindholm

177

Publications

6.1K

Citations

H-Index

Concepts

All Affiliations

Sahlgrenska University Hospital Karolinska Institutet Karolinska University Hospital University of Gothenburg Umeå University

About

Barbro Linderholm is an author at Sahlgrenska University Hospital specializing in oncology, breast cancer, and medicine.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	18	22	2.4K
2	Pathology	14	16	1.8K
3	Cell Biology	6	6	399
4	Health Sciences	4	4	124
5	Obstetrics	3	3	456

Barbro Linderholm

Publications

5.3K

Citations

H-Index

Page 1

	Year	Citations
Adjuvant Olaparib for Patients with <i>BRCA1</i> - or <i>BRCA2</i> -Mutated Breast Cancer Andrew Tutt, Judy E. Garber, Bella Kaufman, New England Journal of Medicine	2021	1.6K
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer Charles E. Geyer, Judy E. Garber, Richard D. Gelber, Annals of Oncology Breast OncologyOverall SurvivalMedicinePathologyGermline Pathogenic Variants	2022	404
Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program Fátima Cardoso, John M.S. Bartlett, Leen Slaets, Annals of Oncology Eortc 10085/Tbcrc/big/nabcgBreast OncologyMedicineGynecologyBreast Imaging	2017	381
Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer Barbro Linderholm, Henrik Hellborg, Unn‐Britt Johansson, Annals of Oncology Surgical OncologyBreast OncologyHigher LevelsShorter Survival TimesMedicine	2009	339
Vascular endothelial growth factor is of high prognostic value in node-negative breast carcinoma. Barbro Linderholm, Björn Tavelin, Kjell Grankvist, Journal of Clinical Oncology	1998	270
Correlation of Vascular Endothelial Growth Factor Content With Recurrences, Survival, and First Relapse Site in Primary Node-Positive Breast Carcinoma After Adjuvant Treatment Barbro Linderholm, Kjell Grankvist, Nils Wilking, Journal of Clinical Oncology	2000	254
p53 and vascular-endothelial-growth-factor (VEGF) expression predicts outcome in 833 patients with primary breast carcinoma Barbro Linderholm, Birgitta Lindh, Björn Tavelin, International Journal of Cancer	2000	153
The expression of vascular endothelial growth factor correlates with mutant p53 and poor prognosis in human breast cancer. Barbro Linderholm, Thomas Lindahl, Lars Holmberg, PubMed Breast OncologyPathologyHuman Breast CancerCancer BiologyTumor Biology	2001	152
Expression of Cyclin E and the Cyclin-Dependent Kinase Inhibitor p27 in Malignant Lymphomas—Prognostic Implications Martin Erlanson, Cajsa Portin, Barbro Linderholm, Blood	1998	139
Tumor Specific VEGF-A and VEGFR2/KDR Protein are Co-expressed in Breast Cancer Lisa Rydén, Barbro Linderholm, Niels Hilmer Nielsen, Breast Cancer Research and Treatment Tumor BiologyBreast OncologyTumor Specific Vegf-aMedicineVegfr2/kdr Protein	2003	119

Page 1